OGN Organon & Co.

NYSE Pharmaceutical Preparations CIK: 0001821825
AI RATING
SELL
72% Confidence

Investment Thesis

Organon faces severe financial distress driven by extreme leverage (9.49x debt-to-equity) and deteriorating fundamentals, with declining revenue (-2.9% YoY) and collapsing EPS (-78.4% YoY) compounded by dangerously weak interest coverage of only 1.9x. While the company maintains positive free cash flow and reasonable operational margins, the unsustainable capital structure and shrinking top-line create material refinancing and solvency risks that outweigh operational strengths.

Strengths

  • + Positive operating cash flow of $225M and free cash flow of $188M provide near-term liquidity
  • + Solid gross margin of 53.6% and acceptable operating margin of 14.6% demonstrate pricing power in core business
  • + Adequate current ratio of 1.97x and quick ratio of 1.42x indicate short-term liquidity is manageable

Risks

  • ! Extreme leverage with 9.49x debt-to-equity ratio and $8.6B long-term debt creates acute refinancing and default risk
  • ! Critically weak interest coverage ratio of 1.9x indicates minimal cushion to service debt from operations
  • ! Revenue decline of 2.9% YoY and EPS collapse of 78.4% YoY signal deteriorating business fundamentals and operational distress

Key Metrics to Watch

Financial Metrics

Revenue
1.5B
Net Income
146.0M
EPS (Diluted)
$0.55
Free Cash Flow
188.0M
Total Assets
13.0B
Cash
1.1B

Profitability Ratios

Gross Margin 53.6%
Operating Margin 14.6%
Net Margin 10.0%
ROE 16.2%
ROA 1.1%
FCF Margin 12.9%

Balance Sheet & Liquidity

Current Ratio
1.97x
Quick Ratio
1.42x
Debt/Equity
9.49x
Debt/Assets
93.1%
Interest Coverage
1.92x
Long-term Debt
8.6B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T12:14:10.817777 | Data as of: 2026-03-31 | Powered by Claude AI